Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
MEDI3617(一种选择性血管生成素-2抑制剂)单药治疗以及与卡铂/紫杉醇、紫杉醇或贝伐珠单抗联合治疗晚期实体瘤的I期研究
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-17-1775
Hyman, David M; Rizvi, Naiyer; Natale, Ronald; Armstrong, Deborah K; Birrer, Michael; Recht, Lawrence; Dotan, Efrat; Makker, Vicky; Kaley, Thomas; Kuruvilla, Denison; Gribbin, Matthew; McDevitt, Jennifer; Lai, Dominic W; Dar, Mohammed